William Blair Analysts Boost Earnings Estimates for Inari Medical, Inc. (NASDAQ:NARI)

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at William Blair upped their Q1 2025 EPS estimates for Inari Medical in a research note issued on Wednesday, July 31st. William Blair analyst M. Kaczor now forecasts that the company will post earnings per share of $0.00 for the quarter, up from their prior forecast of ($0.01). William Blair has a “Outperform” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.62) per share. William Blair also issued estimates for Inari Medical’s Q4 2025 earnings at $0.10 EPS and FY2025 earnings at $0.13 EPS.

NARI has been the subject of a number of other reports. Truist Financial restated a “hold” rating and issued a $55.00 price target (down from $60.00) on shares of Inari Medical in a report on Wednesday. Wells Fargo & Company reduced their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday. Robert W. Baird reduced their price target on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Wednesday. Finally, Canaccord Genuity Group raised their price target on shares of Inari Medical from $55.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Inari Medical currently has an average rating of “Moderate Buy” and an average price target of $60.17.

Inari Medical Trading Down 1.2 %

NASDAQ:NARI opened at $47.31 on Friday. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of -115.39 and a beta of 1.01. The firm has a fifty day simple moving average of $50.14 and a two-hundred day simple moving average of $48.69. Inari Medical has a 12 month low of $36.73 and a 12 month high of $71.85.

Insider Activity

In related news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 465,474 shares in the company, valued at $23,273,700. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $46.60, for a total transaction of $1,864,000.00. Following the transaction, the director now directly owns 925,359 shares in the company, valued at $43,121,729.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now owns 465,474 shares in the company, valued at $23,273,700. The disclosure for this sale can be found here. Insiders sold 222,744 shares of company stock worth $11,494,500 over the last three months. 10.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NARI. Dimensional Fund Advisors LP raised its position in Inari Medical by 7.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock worth $38,693,000 after acquiring an additional 41,555 shares during the period. Norges Bank bought a new stake in Inari Medical in the fourth quarter worth about $29,491,000. New York State Common Retirement Fund raised its position in Inari Medical by 10.7% in the fourth quarter. New York State Common Retirement Fund now owns 311,410 shares of the company’s stock worth $20,217,000 after acquiring an additional 29,983 shares during the period. Knights of Columbus Asset Advisors LLC raised its position in Inari Medical by 99.7% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 45,621 shares of the company’s stock worth $2,962,000 after acquiring an additional 22,780 shares during the period. Finally, Motley Fool Asset Management LLC raised its position in Inari Medical by 46.2% in the first quarter. Motley Fool Asset Management LLC now owns 64,677 shares of the company’s stock worth $3,103,000 after acquiring an additional 20,438 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.